Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Drug Risk

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge about pharmaceutical interventions has historically emphasized efficacy and safety profiles, often framed around population-level outcomes. As this informational heritage evolved, it increasingly accommodated nuanced discussions of adverse effects, particularly those emerging from long-term medication use. This shift in focus naturally extends to the examination of specific drug-exposure scenarios, where the relationship between a therapeutic agent and a rare but serious condition becomes a subject of inquiry. In the domain of mass production, the transition from general health awareness to occupational exposure concern is marked by a pivot from patient-centered risk communication to workplace safety considerations. Here, the legacy of health science information provides a critical backdrop for understanding how exposure to certain compounds, including those used in pharmaceuticals, may pose distinct hazards in manufacturing environments.

Bridging Patient and Occupational Exposure Contexts

The bridge between these contexts lies in the recognition that the same biological pathways relevant to patient outcomes can inform assessments of worker safety, particularly when handling active pharmaceutical ingredients. This transition underscores the need for rigorous exposure monitoring and hazard communication protocols, moving from general health literacy to specific occupational risk management without delving into mechanistic details. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The clinical presentation of ONJ typically involves areas of exposed bone in the jaw that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Animal Studies

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local stressors like dental procedures or infection. Multiscale characterization of jawbone in animal models treated with alendronate has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). In estrogen-deficient rats, treatments with bisphosphonate (alendronate) affected the jawbone, including changes in mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate therapy alters the structural and mechanical properties of the jawbone, potentially predisposing it to necrosis.

Temporal Relationship and Risk Factors

Regarding the timeline between exposure and documented harm, the time to onset of ONJ symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients who develop ONJ have relief of symptoms after stopping the drug, though a subset may experience recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 titled 'Osteonecrosis of the Jaw,' which describes the condition, its association with bisphosphonates including Fosamax, and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, the absolute incidence in clinical trials was low and not statistically different from placebo, which may affect the perception of risk. For affected patients, causation-related considerations include the presence of other risk factors such as cancer, chemotherapy, corticosteroids, or poor oral hygiene, which can confound the attribution of ONJ solely to Fosamax. The label explicitly states that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, establishing a direct causal link in an individual patient requires careful evaluation of the temporal relationship, duration of bisphosphonate exposure, and exclusion of other contributing factors. The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), indicating a recognition of the drug's role in the condition.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

Scientific evidence includes pharmacological mechanisms (inhibition of osteoclast activity leading to suppressed bone remodeling), clinical reports of ONJ in bisphosphonate users, and animal studies showing jawbone alterations. The prescribing information for Fosamax includes a specific warning about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of ONJ symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.